- Home
- MHO vs SLNO Comparison
MHO vs SLNO Comparison
Compare MHO & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHO
- SLNO
- Stock Information
- Founded
- MHO 1976
- SLNO 1999
- Country
- MHO United States
- SLNO United States
- Employees
- MHO N/A
- SLNO N/A
- Industry
- MHO Homebuilding
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- MHO Consumer Discretionary
- SLNO Health Care
- Exchange
- MHO Nasdaq
- SLNO Nasdaq
- Market Cap
- MHO 3.6B
- SLNO 3.8B
- IPO Year
- MHO 1986
- SLNO 2014
- Fundamental
- Price
- MHO $125.05
- SLNO $69.95
- Analyst Decision
- MHO Strong Buy
- SLNO Strong Buy
- Analyst Count
- MHO 3
- SLNO 9
- Target Price
- MHO $163.67
- SLNO $116.78
- AVG Volume (30 Days)
- MHO 255.6K
- SLNO 1.3M
- Earning Date
- MHO 10-22-2025
- SLNO 11-04-2025
- Dividend Yield
- MHO N/A
- SLNO N/A
- EPS Growth
- MHO N/A
- SLNO N/A
- EPS
- MHO 17.05
- SLNO N/A
- Revenue
- MHO $4,475,753,000.00
- SLNO $32,656,999.00
- Revenue This Year
- MHO N/A
- SLNO N/A
- Revenue Next Year
- MHO $2.33
- SLNO $181.30
- P/E Ratio
- MHO $7.33
- SLNO N/A
- Revenue Growth
- MHO 4.77
- SLNO N/A
- 52 Week Low
- MHO $100.22
- SLNO $41.50
- 52 Week High
- MHO $172.23
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- MHO 33.49
- SLNO 58.72
- Support Level
- MHO $122.76
- SLNO $63.55
- Resistance Level
- MHO $134.89
- SLNO $67.93
- Average True Range (ATR)
- MHO 4.92
- SLNO 3.34
- MACD
- MHO -0.76
- SLNO 0.64
- Stochastic Oscillator
- MHO 12.62
- SLNO 70.28
About MHO M/I Homes Inc.
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprise a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.